NexLife vs. Enhance.MD: prices, fine print, and the honest verdict

Tirzepatide pricing

NexLife: $215 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $186/mo (12-month plan). Enhance.MD does not offer tirzepatide.

Semaglutide pricing

On semaglutide, NexLife wins at $165 versus $249 all-in — $84/mo apart. NexLife: Semaglutide runs $165 a month all-in at the standing rate ($145 on intro/plan terms). Enhance.MD: Semaglutide runs $249 a month all-in at the standing rate ($212 on intro/plan terms).

Transparency

NexLife: Source-verified (verified 2026-08-05); names its pharmacy — 6 named partner pharmacies. Enhance.MD: Source-verified (verified 2026-08-08); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

NexLife: none on monthly; cancel any time on monthly. Enhance.MD: none month-to-month; term plans paid per schedule.

Two ladders, side by side

Put both dose ladders on the same axis and the structures argue for themselves: NexLife holds $215 on every rung (four-month titration: exactly $860). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

The semaglutide board

On semaglutide, NexLife prices at $165 against $249 all-in. Both sit against a verified field floor of $133 and Wegovy's flat $349 brand rate; dual-molecule pricing also sets each program's internal switch cost when a plateau raises the tirzepatide question.

The five normalizations, applied to this pair

1 · All-in, not advertised. NexLife's ranked figure is $215, with no membership to add; Enhance.MD publishes no figure to normalize. 2 · Maintenance basis. NexLife is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. NexLife: standing $215, prepaid $186 effective (12-month plan) — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. NexLife: source-verified, read 2026-08-05; Enhance.MD: source-verified, read 2026-08-08. 5 · Pharmacy weighed. NexLife names 6 named partner pharmacies; Enhance.MD names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

NexLife: no membership — the medication figure is the billed figure; prepaid 12-month plan at $186/mo effective; cancel any time on monthly; commitment: none on monthly. Enhance.MD: no membership — the medication figure is the billed figure; prepaid 12-month plan at $212/mo effective; term plans paid per schedule; commitment: none month-to-month. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

NexLife carries source-verified pricing (last read 2026-08-05); pharmacy disclosure is its strong suit — 6 named partner pharmacies, U.S.-licensed 503A compounding pharmacies and FDA-registered 503B outsourcing facilities; fulfillment routed by provider direction, location, and availability; partner network published (6 named). Enhance.MD carries source-verified pricing (last read 2026-08-08); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Moving from NexLife to Enhance.MD (or back) is administratively unglamorous: complete the new program's intake, let its prescriber issue a fresh prescription to its pharmacy, and cancel the old subscription in writing — prescriptions don't transfer between telehealth programs, and neither do prepaid balances, which is the quiet reason month-to-month terms are worth their premium.

Refills, shipping, and the week-to-week reality

The unglamorous layer — how the medication actually reaches you and stays on schedule — splits like this: NexLife: shipping free expedited shipping included; consultation included (provider consultation plus nutrition & fitness support); async visit model. Enhance.MD: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick NexLife if the semaglutide line is cheaper here; you want a price that survives titration; you'll prepay for the $186 effective rate; a named pharmacy is non-negotiable for you. Pick Enhance.MD if its published terms happen to fit your state, format, or timing. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

The dataset's bench is deep; the closest verified third options to this matchup's price band are Yucca Health at $258 (flat, no membership); IVIM Health at $278 (dose-scaled, $75 membership included); Mochi Health at $278 (flat, $79 membership included, named pharmacy) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The brand benchmark both must beat

Neither program exists in a vacuum: FDA-approved Zepbound sits at $449/month at maintenance (LillyDirect or retail KwikPens, ~$350 on TrumpRx, ~$50 for newly eligible Medicare patients), and Wegovy at a flat $349. The cheaper of these two compounded options saves $2,808/year against the Zepbound benchmark — the number that has to justify accepting a not-FDA-reviewed product, per the full trade analysis. When a compounded quote drifts above ~$350, this benchmark starts winning the argument on its own.

The verdict

With incomplete published pricing on one or both sides, get current figures in writing before enrolling with either. Both records, with dates and sources, live in the pricing database.